Why the study?
Prior studies of cardiovascular health and genetic susceptibility did not account for heterogeneity in underlying cardiometabolic-renal states. Whether ideal CVH protects against CVD across the CKM syndrome continuum, and whether this benefit is modified by CKM stage or genetic susceptibility, remained unknown.
Does favorable cardiovascular health (measured by Life's Essential 8) reduce the risk of incident composite cardiovascular disease across the CKM syndrome continuum (Stages 0–3) and polygenic risk strata in adults free of baseline cardiovascular disease?
Does favorable cardiovascular health (measured by Life's Essential 8) reduce the risk of incident composite cardiovascular disease across the CKM syndrome continuum (Stages 0–3) and polygenic risk strata in adults free of baseline cardiovascular disease?
Maintaining ideal cardiovascular health (Life's Essential 8 ≥80) reduces incident cardiovascular disease risk by 53% across the entire CKM syndrome continuum without attenuation in advanced stages, while countering the amplified impact of high polygenic risk in later CKM stages.
Answers are grounded in this paper and cite their sources.
Supports CVH optimization across CKM stages; leaves open whether randomized trials confirm benefit despite genetic risk.
Background: Prior studies of cardiovascular health (CVH) and genetic susceptibility have not accounted for heterogeneity in underlying cardiometabolic-renal states. Whether ideal CVH protects against cardiovascular disease (CVD) across the cardiovascular-kidney-metabolic (CKM) syndrome continuum, and whether this benefit is modified by CKM stage or genetic susceptibility, remains unknown. Methods: This prospective study included 242,951 UK Biobank participants (aged 37–73) in CKM Stages 0–3, free of CVD at baseline (2006–2010), followed through 2022. CVH was quantified using Life’s Essential 8 (LE8) (poor, <50; intermediate, 50–79; ideal, ≥80). A cardiovascular-specific polygenic risk score (PRS) was categorized into tertiles. The primary outcome was incident composite CVD. Multivariable Cox models estimated hazard ratios (HRs); cumulative incidence functions accounting for competing mortality were compared by Gray’s test. Results: Among 242,951 participants (mean age, 55.7 years; 53.1% women), 39,355 incident CVD events occurred over a median follow-up of 15.2 years. Ideal CVH was associated with 53% lower CVD risk versus poor CVH (HR, 0.47; 95% CI, 0.45–0.49), with the largest reductions for heart failure (HF) (HR, 0.33) and coronary heart disease (CHD) (HR, 0.35). Higher CVH was associated with lower CVD risk across genetic risk strata. No CKM × CVH interaction was detected (P = .335), indicating preserved protection across the disease continuum; a significant CKM × PRS interaction (P = .003) indicated amplified polygenic risk impact in advanced stages. Both CVH- and PRS-based stratification significantly separated cumulative CVD incidence across all CKM stages (all Gray’s test P < .001). Results were robust to inverse probability weighting (IPW), competing risk models, and landmark analyses. Conclusion: Favorable CVH was associated with substantially lower CVD risk across the full CKM continuum without attenuation in advanced disease, whereas polygenic risk consequences were amplified in later CKM stages. These findings support integrating CVH assessment as a complementary axis within CKM risk stratification.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: